Outcome myasthenia gravis patients with Covid-19

Abstract Background: Previous data about myasthenia gravis (MG) patients with Covid-19 are sporadic and insufficient to make any conclusion how they affect each other. Therefore, we present our experience with a group of MG patients who were infected with Covid-19.Cases presentation: We present clinical outcome in 13 patients with generalized autoimmune MG and COVID-19. Patients were divided into two groups depending on severity of clinical condition: more severe- those who required hospitalization and group treated at home with milder condition. Almost equal number of patients were in the group of hospitalized (7 patients) and treated at home (6 patients). Only men were in more severe group, while milder group consisted of both sexes equally. Exacerbation of myasthenic weakness developed only in hospitalized patients, among three lethal outcomes. Clinical remission of MG noted in 2 of 3 patients treated with tocilizumab. Clinical course of the disease commented in both groups.Conclusion: more severe clinical conditions and egzarcerbations of MG observed in middle aged male patients predominantly, among 3 of them died.